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CD4 Augments the Response of a T Cell to
Agonist but Not to Antagonist Ligands
Johannes Hampl,* Yueh-hsiu Chien,²³ peptide variants can be due to qualitative and/or quanti-
tative differences in the way the TCR perceives thoseand Mark M. Davis*²³
ligands. Recently, we and others have found evidence*The Howard Hughes Medical Institute
that the affinity of the TCR for antagonist/MHC com-²The Department of Microbiology and Immunology
plexes is lower compared to its affinity for agonist/MHCStanford University School of Medicine
and that the off-rates are often faster (Alam et al., 1996;Stanford, California 94305
Lyons et al., 1996). This suggests that shorter half-lives
of the ternary complexes between TCR and peptide/
MHC might lead to interrupted T cell signals resultingSummary
in T cell antagonism. These studies are consistent with
models in which rather small differences in the affinityThe recognition of peptide variants by the T cell recep-
or dissociation rate between TCR and peptide/MHCtor (TCR) has revealed a wide range of possible re-
complexes are greatly amplified by the TCR signalingsponses. Here, using a series of CD41 and CD42 vari-
machinery into very distinct T cell responses (McKei-ants of the same T cell hybridoma, we find that while
than, 1995; Rabinowitz et al., 1996). These amplificationthe expression of CD4 converts weak agonists into
steps might begin at the plasma membrane with thefull agonists, none of the antagonist peptides are effi-
clustering of TCR-peptide/MHC complexes (Reich et al.,ciently recognized as agonists. Furthermore, in an-
1997) and the engagement of the coreceptor CD4 ortagonist assays, little difference can be seen in the
CD8 and continue on inside the cell (phosphorylationresponse of CD41 and CD42 T cells. Together with
cascades, expression of several ITAM motifs per TCR/previous work showing a marked difference in stability
CD3 unit, etc.) to the nucleus.between TCR binding to agonist versus antagonist
In this report, we analyze the role of CD4 in the recog-ligands, these data suggest that CD4 engagement oc-
nition of agonist and antagonist ligands by T cells. Wecurs after a TCR-peptide/MHC complex has formed
have derived CD41 and CD42 variants of the 2B4 T celland that it requires a certain minimal half-life of the
hybridoma, which is specific for the moth cytochrometernary complex to be fully engaged in signaling.
c peptide 88±103 (MCC) bound to the mouse MHC class
II molecule IEk. We find that all CD41 clones have higherIntroduction
antigen sensitivities and produce more IL-2 than CD42
clones, consistent with previously published data fromCD4-expressing T lymphocytes generally recognize
another T cell hybrid (Marrack et al., 1983). Interestingly,peptide antigens bound to MHC class II molecules.
another effect that we observe is that the presence ofWhile binding to a particular MHC/peptide complex is
CD4 allows weak agonists to berecognized as efficientlyan intrinsic feature of the ab TCR (Matsui et al., 1991,
as the most stimulating peptide. In contrast, the pres-1994; Weber et al., 1992; Corr et al., 1994), the contribu-
ence of CD4 has little effect in antagonist recognition,
tion of CD4 in antigen recognition and T cell activation
suggesting that it plays no role in this phenomenon.
is less clear. Previous work has shown that native CD4
We propose that CD4 can only bind to preformed
enhances the capability of thymocytes and mature T
TCR-peptide/MHC complexes that have a certain mini-
cells to recognize antigen by 30- to 100-fold (Janeway,
mal stability.
1992). Part of this contribution stems from its ability to
recruit the phosphotyrosine kinase p56lck to the TCR/ Results
CD3 complex. Even without its cytoplasmic lck-binding
domain, CD4 still augments T cell reactivity by 3- to
CD41 2B4 T Cell Hybridomas Recognize the MCC
9-fold (Janeway, 1992), possibly because it stabilizes Peptide with Greater Sensitivity
the interaction between TCR and its ligands, as recently than CD42 Clones
shown for CD8 (Garcia et al., 1996).
The 2B4 T cell hybridoma recognizes the MCC peptide
Studies on antigenic peptide variants have revealed
88±103 bound to mouse class II MHC molecule IEk. Many
that the signals transmitted through the T cell receptor sublines of this hybridoma are normally CD4-negative,
(TCR) can produce a wide range of outcomes. Peptides and thus this molecule is apparently not essential for
that are structurally related to stimulatory peptides (ago- antigen recognition. However, at least one variant exists
nists) can either inhibit such an agonist response (antag- that is CD4-positive (R. N. Germain, personal communi-
onists) or activate only some, but not all T cell functions cation), and we took advantage of this heterogeneity to
(partial agonists): there is evidence that peptide variants isolate a number of clones that are either positive or
can be important in positive and negative selection of negative for CD4 (Figure 1). The levels of CD4 for the
thymocytes, in the persistence of viral infections, and positive clones are comparable or slightly higher than
in the modulation of cytokine profiles of peripheral T those of primary mouse CD4-positive T cells (data not
cells in vivo and in vitro (as reviewed by Sette et al., shown). The clones express similar levels of TCR/CD3
1994; Jameson and Bevan, 1995; Kersh and Allen, 1996). complexes (Figure 1 and data not shown), and their
These different reactions of T cells upon encountering phenotype is stable. Both groups of clones exhibit simi-
lar reactivity to phorbol ester and ionomycin, or plate-
bound anti-CD3 antibody (data not shown), but all clones³These two authors contributed equally to this work.
Immunity
380
Figure 1. TCR and CD4 Expression Levels of
Representative 2B4 Hybridoma Clones
The original 2B4 T cell hybridoma was posi-
tively and negatively sorted by FACS for the
expression of CD4 and cloned. CD4-positive
clones (left panel) and CD4-negative clones
(right panel) were picked and analyzed for
their CD4 and CD3 expression with mono-
clonal antibodies GK1.5, conjugated to phy-
coerithrin, and 500a2, conjugated to FITC,
respectively. Gates were set according to un-
stained controls (not shown), and the percent-
age of cells for each quadrant was calculated.
expressing CD4 recognize the MCC peptide with greater MCC-driven IL-2 production and a nearly complete
block in the recognition of T102S (Figure 4).sensitivity than CD42 clones (Figure 2). The MCC con-
centration required for half-maximal IL-2 production is
approximately 10±60 nM for CD41 cells and 100±600 CD4 Expression Does Not Convert Antagonist
Peptides to Agonist Peptides and Has OnlynM for CD42 cells. In addition, CD41 clones produce
on average about 2.5-fold more IL-2 than their CD42 a Small Effect in Antagonist Assays
Since CD4 expression has such a pronounced effect oncounterparts.
the recognition of weak agonists by T cells, we asked
whether this expression would enable the T cells toExpression of CD4 Converts Weak Agonists
into Full Agonists recognize any antagonist peptide as agonist. Surpris-
ingly, most CD41 2B4 cells are not activated by anyNext, we examined the influence of CD4 expression on
the recognition of variant peptides T102S and T102N, antagonist peptides (data not shown), the only excep-
tion being the most sensitive clone (#701), which pro-which have been described as weak agonists in the
MCC system (Matsui et al., 1994; Reay et al., 1994). The duced trace amounts of IL-2 at very high concentrations
of the K99R peptide (Figure 3).CD42 clone exhibits the expected activation pattern,
recognizing the MCC peptide as a full agonist, while the Next, we compared the activity of antagonist peptides
on CD41 and CD42 negative 2B4 clones in inhibitionweak agonists, T102S and T102N, induced a weak IL-2
response. In contrast, T102S and T102N are highly stim- assays. In contrast to agonist assays, where T cell acti-
vation is directly related to the concentration of theulatory for a CD41 clone (Figure 3). All six CD41 and
CD42 clones tested react in the described way (data tested peptide, a comparison of different clones in an-
tagonist assays has to take into account the fact thatnot shown).
To determine whether the expression of CD4 is suffi- the CD41 and CD42 clones differ in their antigen sensi-
tivity and their maximal IL-2 production (Figure 2). Thecient to account for this effect, we added F(ab9) frag-
ments of an anti-CD4 antibody to the cultures. This does reported hierarchy of antagonist peptides in the MCC
system, with K99R as the strongest antagonist, followednot inhibit the recognition of the MCC peptide nor affect
the recognition of theweak agonistT102S by CD4-nega- by T102G (Page et al., 1994; P. A. Reay, unpublished
data) and K99Q (Spain et al., 1994), was not alteredtive clones, showing that they are truly CD4-negative.
However, for the CD41 clones, the addition of anti-CD4 by CD4 expression. The peptide variant K99A neither
stimulated nor antagonized (Lyons et al., 1996) and thusF(ab9) fragments resulted in a moderate reduction in
Figure 2. Antigen Reactivity of 2B4 T Cell Hy-
bridoma Clones
Reactivities of CD4-positive (A) and CD4-
negative (B) clones are shown. The MCC(88±
103) peptide was added at the indicated con-
centrations to 2 3 104/well 2B4 T cells and
2 3 104/well IEk-transfected CHO cells. After
18 hr, the supernatants were analyzed for
their IL-2 content. Background values for the
IL-2 ELISA were around #0.1 U/ml.
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Figure 3. Recognition of MCC Peptide Vari-
ants by a CD4-Positive and a CD4-Negative
2B4 Clone
Reactivities of CD41 clone #701 (A) and
CD42 clone #242 are shown. The MCC pep-
tide and variants were added at the indicated
concentrations to 2 3 104/well 2B4 T cells
and 2 3 104/well IEk-transfected CHO cells.
After 18 hr, the supernatants were analyzed
for their IL-2 content. Background values for
the IL-2 ELISA were around #0.1 U/ml.
served as a null peptide control (Figures 5A and 5B). et al., 1997). When the same clone is tested in the antag-
This effect was not restricted to a single clone, since all onist assays, the antibody simply reduces the overall
three CD41 and three CD42 clones tested showed simi- amount of IL-2 produced (Figure 6B). This inhibition can
lar responses (data not shown). In addition, a careful largely be attributed to the effect of the antibody on the
cross-titration of the agonist peptide MCC and the an- recognition of the agonist peptide, indicating that anti-
tagonist peptide K99R showed that both CD41 and CD4 antibody interferes with this interaction but not with
CD42 T cell hybrids are antagonized to a similar degree. antagonist recognition.We conclude that the expression
The concentration of K99R peptide, necessary to pro- of CD4 has no qualitative effect on the recognition of
duce 50% inhibition, never varied less than 3-fold for antagonist peptides, nor does it influence the efficacy
CD41 clones compared to CD42 clones (Figures 5C and of the antagonist signal.
5D). We believe that such small differences can be inter-
preted as the result of variations from experiment to
experiment. These data indicate that there is no funda- Discussion
mental difference between CD41 and CD42 T cells in
antagonist assays, suggesting that CD4 does not play In this report, we have studied the contribution of CD4
a major role in TCR antagonism. to the recognition of MCC peptide variants by the 2B4
We examined this phenomenon further by adding dif- T cell hybridoma. We find that CD41 2B4 hybridomas
ferent amounts of anti-CD4 F(ab9) fragments to both
are about 10-fold more sensitive for the MCC peptide
agonist and antagonist assays to gauge the effect. In
and produce more IL-2 upon stimulation than CD42
the case of the agonist assay, addition of anti-CD4 anti-
clones (Figure 2), as has been described in other sys-bodies shifted the dose-response curve to the right (Fig-
tems (Marrack et al., 1983). One new observation isure 6A), as has also been observed by others (Madrenas
that peptides T102S and T102N, which stimulate CD42
hybrids only weakly, are seen as full agonists by CD41
cells, shifting the dose-response curve almost 100-fold
(Figure 3). Measurements of the affinity of the 2B4 TCR
for several peptide/IEk complexes (Lyons et al., 1996)
has demonstrated that T102S and T102N/IEk complexes
have a 4- to 5-fold lower affinity and a 6- to 7-fold faster
off-rate than the wild-type MCC/IEk complex (Table 1).
Nevertheless, T cells expressing CD4 can overcome
these differences (Figure 3). This suggests that CD4
either can stabilize the interaction between TCR and
these peptide/IEk complexes in a similar way as CD8
can stabilize TCR/MHC class I interactions (Garcia et
al., 1996) and/or that it can recruit lck into the proximity
of the TCR (resulting in increased sensitivity).
Peptides that can antagonize CD42 2B4 hybrids do
not stimulate CD41 cells efficiently and exhibit similar
activities in antagonist assays using either CD41 or
CD42 cells (Figures 3 and 5). Furthermore, in the experi-
Figure 4. Effect of Anti-CD4 F(ab) Fragments on the Recognition of ment depicted in Figure 6, anti-CD4 antibody shifts the
MCC and T102S Peptides by the 2B4 Hybridoma MCC dose-response curve of a CD41 2B4 clone about
2B4 T cells (2 3 104/well) were cultivated with IEk-transfected CHO 10-fold to the right. However, when added to an antago-
cells (2 3 104/well) and 10 mM MCC, 0.1 mM MCC, or 10 mM T102S nist assay, anti-CD4 reduces overall the IL-2 production
peptide in the absence (shaded bars) or presence (closed bars) of
of the T cells without enhancing or diminishing the de-10 mg/ml anti-CD4 F(ab)fragments. After 18 hr, the supernatants
gree of antagonism. Therefore, the expression of CD4were analyzed for their IL-2 content. Background values for the IL-2
ELISA were around #0.01 U/ml. is not important for the quality of the T cell response
Immunity
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Figure 5. TCR Antagonism of a CD4-Positive
and a CD4-Negative 2B4 Clone
IEk-transfected CHO cells were cultivated for
6 hr in the presence of 1 mM MCC (A and
B) or the indicated concentrations of MCC
peptide (C and D). After harvestingand wash-
ing, the cells were added at 2 3 104/well to
2 3 104/well 2B4 T cells in the presence of
peptide variants K99R, T102G, and K99A (A
and B) or in the absence (circles) or presence
of peptide variants K99R (squares and trian-
gles) (C and D). The T cell clones are either
CD4-positive (closed symbols) or CD4-nega-
tive (open symbols). After 20 hr, the superna-
tants were analyzed for their IL-2 content.
Background values for the IL-2 ELISA were
around #0.01 U/ml.
to antagonist ligands nor for its efficacy. This result is dissociates 3.0±3.5 times slower (0.02 s21, measured at
258C) (Alam et al., 1996). Since it has been shown thatsurprising because the weak agonist ligand T102N/IEk
and the antagonist ligand K99R/IEk have similar affinities CD8 can reduce the off-rate of a TCR from MHC class
I/peptide complexes 10-fold (Garcia et al., 1996), thisfor the 2B4 TCR (320 mM and about 330±500 mM, re-
spectively) and the expression of CD4 has such a pro- phenomenon can be explained by the effect of the core-
ceptor CD8 on the half-life of the ternary complex. Innounced effect on the T cell response to T102N peptide.
The major difference between these two complexes is the 2B4 system, weak agonist ligands dissociate from
the TCR with an off-rate of about 0.4 s21, compared toan approximately 10-fold increase in the off-rate from
the 2B4 TCR (0.44 s21 and 4.8 s21, respectively). This MCC/EK, which dissociates 6±7 times slower (0.05 s21).
Antagonist ligands dissociate about 100-fold fastersuggests that the off-rate, i.e., the average half-life of a
TCR/peptide/MHC complex, is more important for the ($5.0 s21, all measured at 258C), and their biological
activity for the 2B4 hybridoma is not changed if CD4 isbiological function of a peptide variant than simple TCR
occupancy, i.e., Kd value (Matsui et al., 1994; Lyons et expressed (Figures 3 and 5).This suggests that corecep-
tors are able to influence the detection of those TCRal., 1996), and this half-life also appears to be decisive
whether CD4 contributes to antigen recognition. How- ligands by T cells that have an up to 10-fold faster disso-
ciation constant from the TCR, compared to full agonistever, one might argue that antagonist peptides deliver
a qualitatively different signal to theT cells, which cannot ligands (Range: 0.2±0.5 s21 at 258C). Within this window,
it is possible that peptides can change their biologicalbe augmented by CD4. We think that this is rather un-
likely because K99R can induce the most sensitive clone activities. Extremely transient interactions with the TCR,
like the K99R/Ek complex, are almost insensitive to the(#701) to produce marginal amounts of IL-2 at very high
concentrations (100 mM) (Figure 3A). In addition, K99R presence of coreceptors, probably because the com-
plexes are so unstable (half lives of #0.2 s21). This hy-activates T cells from 2B4 transgenic mice quite effi-
ciently (J. H. and L. J. Berg, unpublished data). Besides pothesis is supported by the analysis of intracellular
signaling events following TCR ligation: tyrosine phos-our TCR system, three reports have described the con-
version of antagonist peptides into weak agonists upon phorylation of ZAP-70, CD3e, and z chains that follow
TCR ligation is different, if weak agonist peptides rathercoreceptor expression of the T cells (Jameson et al.,
1994; Mannie et al., 1995; Vidal et al., 1996). For T cells than full agonist peptides are being presented (Sloan-
Lancaster et al., 1994; Madrenas et al., 1995). Any inter-expressing the 149.42 TCR, higher CD8 expression lev-
els resulted in the recognition of ovalbumin peptide E1 ference with the recruitment of CD4 to the TCR complex
engaged by full agonist ligands changes the phosphory-as agonist rather than antagonist (Jameson et al., 1994).
The E1 ligand dissociates from the TCR with an off-rate lation state of CD3e, z chains, and ZAP-70 from an ago-
nist to a partial agonist±like pattern (Madrenas et al.,of about 0.07 s21, while theagonist ligand, ovalbumin/Kb,
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Two distinct models of CD4 function have been pro-
posed in the literature: one predicts that CD4 binds to
the MHC molecule simultaneously with the TCR (Jane-
way, 1992). In such a case, the affinity of CD4 for MHC
molecules has to be lower than the affinity of the TCR
for the MHC/peptide complex to ensure specificity
(Brady and Barclay, 1996). Here, this means that CD4
would bind to MHC molecules with an affinity below that
of the TCR and T102G/Ek complexes, i.e., $1 mM, which
is the lowest affinity ligand used in this study. It isdifficult
to imagine how such a low affinity interaction can con-
tribute in a detectable way to the recognition of the
MCC peptide (Figure 2), while not increasing the efficacy
of T102G/Ek-transduced signals (Figures 5A and 5B).
Therefore, we prefer a second model, proposed by R.
Germain and colleagues (Madrenas and Germain, 1996;
Madrenas et al., 1997), that suggests that CD4 stabilizes
already formed clusters of TCR/ligand. This can be
achieved if (1) CD4 can only bind to oligomerized MHC/
peptide complexes but not to monomeric MHC mole-
cules and/or if (2) CD4 binds to the MHC/peptide com-
plex at a much slower pace than the TCR, so that the
whole complex is assembled through a TCR/peptide/
MHC intermediate. This ªsequential engagementº model
predicts that there be a certain minimal half-life of the
TCR/MHC/peptide complex for CD4 to bind. This would
explain why CD4 supports the recognitionof optimal and
suboptimal TCR ligands without effecting the efficacy of
TCR-transduced signals of extremely weak (e.g., antag-
onists) TCR ligands. One possible reason for a time
delay in CD4 recruitment might be the need for TCR/
peptide/MHC molecules to oligomerize before CD4 can
bind. Such oligomerization in the absence of CD4 was
recently shown (Reich et al., 1997). Once such an oligo-Figure 6. Anti-CD4 and TCR Antagonists Inhibit 2B4 T Cell Activa-
mer was formed, the two independent CD4 binding sitestion through an Independent Mechanism
on the MHC class II molecule (Cammarota et al., 1992;(A) Agonist assay. A CD41 2B4 clone (#701) was cultivated at 2 3
Konig et al., 1992, 1996) might be employed in some104/well with 2 3 104/well IEk-transfected CHO cells and MCC pep-
tide in the absence (closed circles) or presence of various amounts way that facilitates multiple CD4s to bind. This would
of anti-CD4 F(ab) fragments (open symbols). also explain why it has been difficult to show direct
(B) Antagonist assay. IEk-transfected CHO cells were cultivated for CD42 MHC class II binding in a monomeric situation (as
6 hr in the presence of 10 nM MCC peptide. After harvesting and
discussed by Brady and Barclay, 1996).washing, the cells were added at 2 3 104/well to 2 3 104/well 2B4
Recruitment of CD4 to the TCR MHC/peptide complexT cells (clone #701) in the presence of the indicated concentrations
can be instrumental for proper T cell activation. Here,of peptide analogs K99R and the absence (closed circles) or pres-
ence (open symbols) of various amounts of anti-CD4 F(ab) frag- we present evidence that this recruitment of CD4 is
ments. After 18 hr, the supernatants were analyzed for their IL-2 strongly dependent on the half life of the ternary com-
content. Background values for the IL-2 ELISA were around #0.01 plex itself. The capability of CD4 to influence the percep-
U/ml. tion of TCR ligands by T cells is limited to both full
agonist peptides and antagonist peptides and is maxi-
1997). Also consistent with the data presented here is mal in the gray zone between agonist and antagonist
an analysis of the activation status of p56lck that shows ligands. Our data can best be explained with models of
that lck is only activated if agonist but not antagonist T cell activation where CD4 joins already formed TCR
peptide is presented to the T cells (Windhagen et al., MHC/peptide complexes. The stability of this complex
determines the extent of CD4 recruitment. TCR ligands1995).
Table 1. Affinity and Kinetics of the Interaction between the 2B4 TCR and Various IEk/MCC Complexes
Peptide Biological Activity Kd [mM] koff [S21] t(1/2) at 258C
MCC Agonist 60 0.06 12 sec
MCC (T102S) Weak agonist 240 0.36 2 sec
MCC (T102N) Weak agonist 320 0.44 2 sec
MCC (K99R) Antagonist 330±500 4.8 0.1±0.2 sec
MCC (T102G) Antagonist 900±1200 5.1 0.1±0.2 sec
MCC (K99Q) Weak antagonist z2000 .5.1 ,0.1 sec
Data from Lyons et al., 1996.
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Production of F(ab) Fragments from Anti-CD4that can engage the TCR for at least 1±2 seconds (at
Antibody GK1.5258C) depend on CD4 to activate T cells. Interactions
F(ab) fragments of the anti-CD4 antibodyGK1.5 (rat IgG2b) (Dialynasbetween TCR and TCR ligands that last longer are in-
et al., 1983) were produced using preactivated papain according to
creasingly independent of CD4, while less stable ones a standard protocol. The digest was size-purified on a Superdex
cannot be supported by CD4. This model raises the S200 column (Pharmacia, Uppsala, Sweden), and fractions were
analyzed by SDS±PAGE. Fractions corresponding to a molecularintriguing possibility that the extent of coreceptor re-
weight range of 40±80 kD awere analyzed for CD4 binding on acruitment determines the biological activity of peptides
BIAcore instrument, using amino-coupled soluble CD4 as ligand.for T lymphocytes. Other molecules that are involved in
This method confirmed a monovalent binding activity of the majorT cell activation, like CD28, CD45 or LFA-1, may also
protein peak to CD4. Active fractions were pooled, concentrated,
influence the perception of these TCR ligands by T cells. filtered, and stored in PBS until use.
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